Investors in Organon & Co. are urged to inquire about a potential securities class action investigation by Rosen Law Firm.
💰 HEY, INVESTORS! 💼
Listen up! The Rosen Law Firm, a badass global investment rights law firm, is investigating Organon & Co. (NYSE: OGN) for potentially misleading shareholders. Here's the lowdown:
The Rosen Law Firm suspects that Organon may have dished out some phony business info to the public. The main focus? Claims that Organon might've kept quiet about its top priority for capital allocation through quarterly dividends.
Now let's get into the nitty-gritty: Organon recently chopped its quarterly dividend from a hefty $0.28 to a meager $0.02 per share. The reduction? A debt-slashing move following the acquisition of Dermavant, which the firm claims Organon management secretly prioritized, all while making overly optimistic statements about the company's overall performance.
When the real deal dropped, the stock value took a 26.9% nosedive. No bueno.
So if you've got Organon securities, you might be entitled to some compensation without shelling out a dime upfront. The Rosen Law Firm is cooking up a class action suit to recover them losses. To get in on the action, head to https://rosenlegal.com/submit-form/?case_id=39817 or phone toll-free at 866-767-3653 or email [email protected] for all the deets.
The Rosen Law Firm has a track record of success handling securities class actions and shareholder derivative litigation. In fact, they once scored the largest ever securities class action settlement against a Chinese Company. The firm has also consistently ranked as the leader in securities class action settlements since 2013, recovering hundreds of millions for investors. In 2020, founding partner Laurence Rosen was even named a Titan of Plaintiffs' Bar by law360.
Stay updated on the case by following the Rosen Law Firm on LinkedIn, Twitter, or Facebook:
✅ LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm/✅ Twitter: https://twitter.com/rosen_firm✅ Facebook: https://www.facebook.com/rosenlawfirm/
Legal mumbo jumbo time: This press release contains attorney advertising. Past results do not guarantee future outcomes.
📧 Contacts:
💼 Laurence Rosen, Esq.📞 Phillip Kim, Esq.📍 The Rosen Law Firm, P.A.🏢 275 Madison Avenue, 40th Floor, New York, NY 10016📞 (212) 686-1060📞 Toll Free: (866) 767-3653📨 [email protected]🌐 www.rosenlegal.com
Article Author: Business Wire https://www.businesswire.com
- The Rosen Law Firm's investigation into Organon & Co. (NYSE: OGN) suspects that the company may have distorted its personal-finance and business news by concealing its focus on capital allocation through quarterly dividends.
- The reduction in Organon's quarterly dividend, from $0.28 to $0.02 per share, and the subsequent 26.9% stock drop, allegedly occurred due to the company's prioritization of a debt-slashing move following the acquisition of Dermavant.
- For Organon shareholders, staying updated on the Rosen Law Firm's class action suit could potentially lead to compensation and might result from the firm's efforts to recover the losses due to the company's alleged misleading financial information.
